pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda.
BACKGROUND
The members of the retinoblastoma protein family, pRb, p107 and pRb2 (p130), are central players in controlling the cell cycle. Whereas disturbed function of pRb is commonly seen in human cancers, it is still an open question whether pRb2 is involved in tumorigenic processes. However, altered subcellular localization of pRb2 and mutations in the pRb2-encoding gene RBL2 have been described for some tumours, including Burkitt lymphomas (BL).


METHODS
We retrieved 51 biopsy specimens of endemic BL cases from Uganda. The expression of pRb2 was determined by immunohistochemistry. Exons 1922 of the RBL2 gene, the region known to contain a nuclear localization signal, were screened for mutations by PCR amplification and direct DNA sequencing.


RESULTS
Nearly all of our cases (84.0%) were positive for pRb2 protein expression although this protein is a marker for growth arrest and Burkitt lymphoma is characterized by a high proliferation rate. Of the positive cases, 73.8% were scored as expressing the protein at a high level. Subcellular pRb2 localization was predominantly nuclear and no cases with expression restricted to the cytoplasm were observed. We did not detect any RBL2 mutations in the part of the gene that encodes the C-terminal end of the protein.


CONCLUSIONS
The majority of endemic BL cases from Uganda express pRb2, but somatic RBL2 mutations affecting the protein's nuclear localization signal appear to be rare.
Kalungi
Sam
S
Section for Pathology, the Gade Institute, University of Bergen, Bergen, Norway. skalungi@gmail.com
Steine
Solrun J
SJ
Wabinga
Henry
H
Bostad
Leif
L
Molven
Anders
A
Am J Pathol. 2000 Mar;156(3):751-60
10702389
Clin Cancer Res. 1999 Jun;5(6):1455-8
10389932
Afr Health Sci. 2007 Sep;7(3):166-75
18052871
Cancer Res. 2000 Jan 1;60(1):8-12
10646842
Br J Cancer. 2000 Nov;83(9):1161-7
11027429
Int J Cancer. 2008 Dec 1;123(11):2658-63
18767045
Genes Dev. 1996 Jul 1;10(13):1633-44
8682294
Hum Pathol. 2001 Apr;32(4):360-7
11331952
Oncogene. 1993 Dec;8(12):3465-8
8247552
Am J Hematol. 2007 Mar;82(3):238-9
16955460
Cancer Lett. 2004 Jan 8;203(1):1-12
14670612
Cancer Res. 1991 Oct 1;51(19):5118-22
1655245
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1250-6
16835319
Clin Cancer Res. 2002 Jun;8(6):1808-15
12060621
Cancer Res. 2000 Jan 15;60(2):383-9
10667591
Hum Pathol. 2002 Jul;33(7):723-31
12196924
Oncogene. 2006 Aug 28;25(38):5257-62
16936745
J Cell Biochem. 2007 Dec 15;102(6):1400-4
17979151
Clin Cancer Res. 1999 Dec;5(12):4065-72
10632341
J Invest Dermatol. 2008 Nov;128(11):2575-2595
18927540
Oncogene. 2006 Aug 28;25(38):5220-7
16936740
Cancer Res. 1991 Jan 1;51(1):89-93
1670995
FASEB J. 1993 Jul;7(10):846-54
8344484
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8751-5
1978938
Clin Cancer Res. 1997 Oct;3(10):1691-7
9815552
Mol Cell Biol. 2002 Jan;22(2):453-68
11756542
Clin Cancer Res. 2005 May 1;11(9):3265-73
15867222
Mol Pathol. 2001 Oct;54(5):331-7
11577176
Hum Pathol. 2008 Jun;39(6):817-23
18436278
Cancer Res. 2001 Jun 15;61(12):4651-4
11406530
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4629-32
8643454
Hum Pathol. 2001 Jan;32(1):4-9
11172288
Carcinogenesis. 2004 Aug;25(8):1485-94
15059924
Genes Dev. 1996 Jul 1;10(13):1621-32
8682293
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6933-8
9192669
Cancer Res. 1990 Nov 15;50(22):7184-9
1977515